[Treatment of airway inflammation in cystic fibrosis].

Abstract

Cystic fibrosis airway inflammation is characterized by neutrophilic efflux and high levels of proinflammatory cytokines such as IL-8 and IL-6. Inhaled corticosteroids are widely used despite lack of evidence of efficacity. Despite evidence of efficacity of ibuprofen, many clinicians have chosen not to use this therapy because of concerns regarding potential side effects. Azithromycin has antiinflammatory properties and is effective in cystic fibrosis (CF) patients. Deoxyribonuclease (rhDNase) has been shown to improve lung function in patients with cystic fibrosis and may also have a positive effect on inflammation. Other antiinflammatory drugs are in the process of validation.

• Authors: M Abély
• Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie (Arch Pediatr) Vol. 14 Issue 11 Pg. 1350-5 (Nov 2007) ISSN: 0929-693X [Print] France
• Vernacular Title: Traitement de l'inflammation bronchique dans la mucoviscidose.
• PMID: 17702549 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Anticoagulants
• Antiviral Agents
• Leukotriene Antagonists
• Recombinant Proteins
• Secretory Leukocyte Peptidase Inhibitor
• Interleukin-10
• Docosahexaenoic Acids
• DNASE1 protein, human
• Deoxyribonuclease I

Topics

• Anti-Bacterial Agents (therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Anticoagulants (therapeutic use)
• Antiviral Agents (therapeutic use)
• Cystic Fibrosis (complications)
• Deoxyribonuclease I (therapeutic use)
• Docosahexaenoic Acids (therapeutic use)
• Humans
• Inflammation (drug therapy, etiology)
• Interleukin-10 (therapeutic use)
• Leukotriene Antagonists (therapeutic use)
• Recombinant Proteins (therapeutic use)
• Secretory Leukocyte Peptidase Inhibitor (therapeutic use)